glp 1 drugs and vision problems GLP-1 are associated with a 35% higher risk of NAION, an eye condition that can cause sudden loss. About 6 to 10 extra cases per 10,000 users over 3 years Investigating Vision Changes Linked to
Description
No statistically significant differences were observed for other neurodegenerative outcomes, including vascular dementia or Parkinsons disease
Moreover, GLP-1 drugs such as semaglutide and liraglutide have demonstrated strong efficacy in improving glycemic control
In addition, first oral GLP-1 receptor agonist (oral semaglutide) was recently approved ( Table 1
Delivery is typically 57 days within those regions and 714 days internationally
Dehydration risk, pancreatitis history, diabetic retinopathy, and rapid weight loss also warrant closer monitoring
125 MackCMSoaresCJWilsonJKAthanacioJRTurekVFTrevaskisJLet al
